Biogen Stock Forecast, Price & News

Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

29 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 12 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biogen stock.
View analyst ratings for Biogen or view top-rated stocks.

How has Biogen's stock price been impacted by COVID-19 (Coronavirus)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has decreased by 19.9% and is now trading at $235.74.
View which stocks have been most impacted by COVID-19.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings data on Tuesday, October, 19th. The biotechnology company reported $4.77 earnings per share for the quarter, beating the Zacks' consensus estimate of $4.09 by $0.68. The biotechnology company had revenue of $2.78 billion for the quarter, compared to analysts' expectations of $2.67 billion. Biogen had a net margin of 13.93% and a trailing twelve-month return on equity of 28.36%. The company's quarterly revenue was down 17.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.84 earnings per share.
View Biogen's earnings history.

How will Biogen's stock buyback program work?

Biogen declared that its board has approved a stock buyback program on Monday, December 23rd 2019, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share guidance of $18.850-$19.350 for the period, compared to the Thomson Reuters consensus estimate of $18.610. The company issued revenue guidance of $10.80 billion-$10.90 billion, compared to the consensus revenue estimate of $10.76 billion.

What price target have analysts set for BIIB?

29 Wall Street analysts have issued 12-month price targets for Biogen's shares. Their forecasts range from $245.00 to $502.00. On average, they expect Biogen's share price to reach $373.45 in the next twelve months. This suggests a possible upside of 58.4% from the stock's current price.
View analysts' price targets for Biogen or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?

Biogen's management team includes the following people:

• Michel Vounatsos, Chief Executive Officer & Director
• Alphonse Galdes, EVP-Pharmaceutical Operations & Technology
• Michael R. McDonnell, Chief Financial Officer & Executive Vice President
• Alfred W. Sandrock, Executive Vice President-Research & Development (LinkedIn Profile)
• Mark Hernon, Chief Information Officer & Senior Vice President

What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Who are some of Biogen's key competitors?

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Novavax (NVAX), Incyte (INCY), Exact Sciences (EXAS), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of BIIB's competitors.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (11.07%), BlackRock Inc. (9.46%), Wellington Management Group LLP (3.80%), Geode Capital Management LLC (1.89%), Bank of New York Mellon Corp (1.10%) and American Century Companies Inc. (0.78%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Renaissance Technologies LLC, Point72 Asset Management L.P., Primecap Management Co. CA, Citadel Advisors LLC, Bank of New York Mellon Corp, Geode Capital Management LLC, and American Century Companies Inc.. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

Which major investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nordea Investment Management AB, Assenagon Asset Management S.A., Squarepoint Ops LLC, Man Group plc, Caption Management LLC, Wedge Capital Management L L P NC, and Massachusetts Financial Services Co. MA.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $235.74.

How much money does Biogen make?

Biogen has a market capitalization of $34.63 billion and generates $13.44 billion in revenue each year. The biotechnology company earns $4.00 billion in net income (profit) each year or $10.22 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,100 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

Where are Biogen's headquarters?

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (617) 679-2000, via email at [email protected], or via fax at 617-679-2617.